Home › Depression › NCT07528014

ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adults (≥18 years) of any gender identity presenting for care with a depressed mood.
* Prescribed treatment with esketamine, conventional TMS, or SAINT as part of standard clinical care.
* Able to provide informed consent and comply with all study requirements.

Exclusion Criteria:

* Any condition deemed by the investigator to preclude safe participation in study assessments.

About the study

This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings. The study will examine outcomes among patients treated with interventions including esketamine, conventional transcranial magnetic stimulation (TMS), or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). Retrospective clinical and research data from existing databases may also be incorporated, when available and authorized, to support model development and validation. The goal is to assess whether integrated clinical datasets can be used to support the development of predictive tools that may inform personalized treatment selection in depression.

Sponsor: Salma Health, Inc. · Participants: 5,000 · Started: Mar 25, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07528014

Locations in the U.S.

Conditions

• Depression
• Treatment-Resistant Depressive Disorder
• Major Depressive Disorder

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.